Chamath Palihapitiya

Chamath Palihapitiya × Jason Calacanis × David Sacks × David Friedberg

Nvidia’s $96.2B revenue and $60B net profit came with 70% growth guidance versus the Street’s 45%, despite supply constraints.Salesforce’s 20%+ rally on $5.90 adjusted EPS and a $46B guide suggests agents may reinforce horizontal systems of record, while vertical SaaS remains contested.Debt also bears watching: $10T must be refinanced within 12 months at a 5.2% 30-year rate.

Chamath Palihapitiya × Jason Calacanis × David Sacks × David Friedberg

The panel’s most aggressive macro signal is 5%-6% U.S.GDP growth in 2026, supported by AI productivity, tax refunds, capital investment, and possible rate cuts, while California’s proposed 5% wealth tax creates a migration and asset-pricing risk.Copper, Polymarket, Huawei, and Amazon supply the clearest upside calls, but software maintenance, entry-level white-collar work, oil, the dollar, and California luxury property remain key disruption or downside themes.

Chamath Palihapitiya × Jason Calacanis × David Sacks × David Friedberg × Brad Gerstner

Trump’s first-phase Gaza deal pairs a ceasefire and unrestricted aid with hostage and prisoner releases plus an initial Israeli withdrawal, though “the Middle East has a way of disappointing you.”The panel linked regional stability to oil monetization and investment, while the Chicago dispute exposed unresolved risks around federal enforcement, political consent, and the roughly $100,000-per-deportation cost cited for ICE.

Chamath Palihapitiya × Jason Calacanis × David Sacks × David Friedberg

Trump’s targeted strikes and ceasefire reduced the feared forever-war risk, while oil rising only from roughly $60 to $74 suggested markets priced a less chaotic Middle East.Mamdani’s New York upset exposed an indebted, “negative capital” generation, and the panel linked his urban-socialist platform to student debt growing from $500 billion to $2 trillion.Stocks reached all-time highs amid a split between weakening breadth and possible liquidity-driven upside, while early FOXO3 cell-therapy results and AI copyright rulings leave major scientific and legal risks unresolved.